Biphenyl

Biphenyl

SCHEMBL7167410

COC(=O)c1cc(Br)c(-c2ccc(O[Si](C)(C)C(C)(C)C)cc2)c(I)c1.c1ccc(-c2ccccc2)cc1

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PREP P48147 4/20 0.40
PDK2 Q15119 1/20 0.40
EGFR P00533 1/20 0.39
ABL1 P00519 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
SGK1 O00141 1/20 0.37
CAMKK2 Q96RR4 1/20 0.37
GABRA5 P31644 1/20 0.37
ACLY P53396 1/20 0.36
NOTUM Q6P988 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
AXL P30530 1/20 0.35
TSHR P16473 1/20 0.35
PTPN1 P18031 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6705270 0.94 PREP (0.44) PREPPDK2ABL1NOTUMCA12
SCHEMBL6058804 0.85 PREP (0.46) PREPCA12CA1CA9
SCHEMBL6697474 0.74 HTR1D (0.39) PREPPDK2NOTUMALDH1A1
SCHEMBL6698482 0.73 ABL1 (0.43) PDK2EGFRABL1SMN1; SMN2GABRA5
SCHEMBL6701789 0.73 HPGD (0.47) PREPABL1SMN1; SMN2ALDH1A1
SCHEMBL8906116 0.73 CA1 (0.56) PREPNOTUMCA12CA1CA2
SCHEMBL16171288 0.73 PREP (0.51) PREPSMN1; SMN2CA12CA1CA2
SCHEMBL6058993 0.72 PREP (0.41) PREPCA12CA1CA9
SCHEMBL6860354 0.72 ABL1 (0.42) PREPPDK2EGFRABL1SMN1; SMN2
Ammonia Solution, Strong SCHEMBL6697477 0.71 ABL1 (0.41) PREPPDK2EGFRABL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6563008-B2 Treatment of disorders linked to hypofolliculinemia and of certain estrogen-dependent pathologies such as prostatic adenomas or carcinomas, and of benign tumours of the breast AVENTIS PHARMA S.A. (FR) 2003-05-13 US disclosed